ストックスクリーナーアプリを入手
2.20
3.77%
0.08
アフターアワーズ：
2.21
0.010
+0.45%
Caribou Biosciences Inc (CRBU) 最新ニュース
Investment Recap: Should you avoid Caribou Biosciences Inc stock right now2026 Market WrapUp & AI Based Buy/Sell Signal Reports - baoquankhu1.vn
Caribou Biosciences (NASDAQ: CRBU) schedules virtual annual meeting June 17, 2026 - Stock Titan
CRBU News | CARIBOU BIOSCIENCES INC (NASDAQ:CRBU) - ChartMill
CRBU Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Caribou Biosciences' (CRBU) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
H.C. Wainwright Maintains Caribou Biosciences(CRBU.US) With Buy Rating, Maintains Target Price $9 - Moomoo
CRBU Forecast, Price Target & Analyst Ratings | CARIBOU BIOSCIENCES INC (NASDAQ:CRBU) - ChartMill
Earnings Miss: How does Caribou Biosciences Inc compare to its peersWeekly Profit Report & Long-Term Capital Growth Strategies - baoquankhu1.vn
CRBU SEC FilingsCaribou Biosciences, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Caribou Biosciences, Inc. (CRBU) stock price, news, quote and history - sg.finance.yahoo.com
Alpha Cognition Inc. (ACOG) Jumps 8.6%: Does the Stock Have More Room to Grow? - Bitget
CRBU Earnings History & Surprises | EPS & Revenue Results | CARIBOU BIOSCIENCES INC (NASDAQ:CRBU) - ChartMill
Caribou Biosciences Granted FDA RMAT Designation for CB-011 Allogeneic Anti-BCMA CAR-T Cell Therapy - Minichart
Caribou Biosciences, Inc. Announces the FDA Granted Regenerative Medicine Advanced Therapy Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy - marketscreener.com
Caribou Biosciences Gains RMAT Status for CB-011 Therapy - TipRanks
Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy - Investing News Network
Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy - Bitget
Caribou rises on FDA RMAT designation (CRBU:NASDAQ) - Seeking Alpha
Caribou Biosciences Announces The FDA Granted Regenerative Medicine Advanced Therapy (Rmat) Designation To Cb-011 - TradingView
Caribou Biosciences receives FDA RMAT designation for CB-011 in multiple myeloma - tradersunion.com
FDA grants RMAT designation to Caribou (CRBU) CAR-T CB-011 in multiple myeloma - Stock Titan
FDA gives advanced therapy status to Caribou's myeloma CAR-T - Stock Titan
Fed Watch: Can Caribou Biosciences Inc expand its profit marginsMarket Activity Recap & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
Is Caribou Biosciences Inc a cyclical or defensive stockWeekly Trade Recap & High Conviction Buy Zone Picks - baoquankhu1.vn
Caribou Biosciences (NASDAQ:CRBU) Stock Rating Upgraded by Truist Financial - marketbeat.com
Hedge Fund Moves: Is Caribou Biosciences Inc stock good for income investors2026 Retail Activity & Daily Market Momentum Tracking - baoquankhu1.vn
How does Caribou Biosciences Inc compare to its peersPortfolio Gains Report & Fast Gaining Stock Reports - baoquankhu1.vn
Caribou Biosciences stock faces pressure amid biotech sector volatility and pipeline updates - AD HOC NEWS
Bronstein, Gewirtz & Grossman, LLC Is Investigating Caribou Biosc - The National Law Review
Caribou Biosciences stock faces pressure amid biotech volatility and pipeline updates - AD HOC NEWS
Caribou Biosciences Shares Double After Strong Multiple Myeloma Trial Results - msn.com
Market Catalysts: Is Caribou Biosciences Inc benefiting from interest rate changesWeekly Risk Summary & Real-Time Buy Zone Alerts - baoquankhu1.vn
Trading Action: How does Caribou Biosciences Inc compare to its peersInsider Buying & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
Caribou Biosciences: Antlers Up For The Allogenic CAR-T Bet Trading At Cash Value - Seeking Alpha
Caribou Biosciences Teases vispa-cel Phase 3 LBCL Plan, Eyes Financing at Leerink Conference - MarketBeat
CRBU Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Analysts Are Bullish on Top Healthcare Stocks: Caribou Biosciences (CRBU), Oncology Institute (TOI) - The Globe and Mail
Drug Pricing Reforms Threaten Caribou Biosciences’ Future Margins and Market Access - The Globe and Mail
Caribou Biosciences: Advancing Allogeneic Cell Therapy Pipeline and Pivotal Trial Plans Support High-Risk Buy Rating - TipRanks
Truist reiterates Buy on Caribou Biosciences stock, $7 target - Investing.com Australia
Truist reiterates Buy on Caribou Biosciences stock, $7 target By Investing.com - Investing.com UK
Caribou Biosciences, Inc. (CRBU) reports Q4 loss, tops revenue estimates - MSN
Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - Investing News Network
Caribou Biosciences earnings beat by $0.04, revenue topped estimates - Investing.com Canada
Caribou Biosciences, Inc. (CRBU) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Caribou Biosciences (NASDAQ:CRBU) Posts Earnings Results, Beats Estimates By $0.05 EPS - MarketBeat
Caribou Biosciences announces Q4 and FY2025 financial results - Traders Union
Caribou Biosciences Q4 licensing revenue rises, net loss narrows - TradingView
Insights into Caribou Biosciences Q4 Earnings - Benzinga
Caribou Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):